Retinoic acid signaling sensitizes hepatic stellate cells to NK cell killing via upregulation of NK cell activating ligand RAE1
- PMID: 17673545
- DOI: 10.1152/ajpgi.00212.2007
Retinoic acid signaling sensitizes hepatic stellate cells to NK cell killing via upregulation of NK cell activating ligand RAE1
Abstract
Hepatic stellate cells (HSCs) store 75% of the body's supply of vitamin A (retinol) and play a key role in liver fibrogenesis. During liver injury, HSCs become activated and susceptible to natural killer (NK) cell killing due to increased expression of the NK cell activating ligand retinoic acid early inducible gene 1 (RAE-1). To study the mechanism by which RAE-1 is upregulated in HSCs during activation, an in vitro model of cultured mouse HSCs was employed. RAE-1 was detected at low levels in quiescent HSCs but upregulated in 4- and 7-day cultured HSCs (early activated HSCs), whereas 21-day cultured HSCs (fully activated HSCs) lost RAE-1 expression. High levels of RAE-1 in 4- and 7-day cultured HSCs correlated with their susceptibility to NK cell killing, which was diminished by treatment with RAE-1 neutralizing antibody. Furthermore, retinoic acid (RA) and retinal dehydrogenase (Raldh) levels were upregulated in early activated HSCs compared with quiescent or fully activated HSCs. Blocking RA synthesis by the Raldh inhibitor or blocking RA signaling by the retinoic acid receptor antagonist abolished upregulation of RAE-1 whereas treatment with RA induced RAE-1 expression in HSCs. In conclusion, during activation, HSCs lose retinol, which is either secreted out or oxidized into RA; the latter stimulates RAE-1 expression and sensitizes early activated HSCs to NK cell killing. In contrast, fully activated HSCs become resistant to NK cell killing because of lack of RAE1 expression, leading to chronic liver fibrosis and disease.
Similar articles
-
Suppression of innate immunity (natural killer cell/interferon-γ) in the advanced stages of liver fibrosis in mice.Hepatology. 2011 Apr;53(4):1342-51. doi: 10.1002/hep.24190. Hepatology. 2011. PMID: 21480338 Free PMC article.
-
Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners.Gastroenterology. 2006 Feb;130(2):435-52. doi: 10.1053/j.gastro.2005.10.055. Gastroenterology. 2006. PMID: 16472598
-
Activation of natural killer cells inhibits liver fibrosis: a novel strategy to treat liver fibrosis.Expert Rev Gastroenterol Hepatol. 2007 Oct;1(1):173-80. doi: 10.1586/17474124.1.1.173. Expert Rev Gastroenterol Hepatol. 2007. PMID: 19072444 Review.
-
Retinoic acids and hepatic stellate cells in liver disease.J Gastroenterol Hepatol. 2012 Mar;27 Suppl 2:75-9. doi: 10.1111/j.1440-1746.2011.07007.x. J Gastroenterol Hepatol. 2012. PMID: 22320921 Review.
-
Regulatory CD4+ T cells modulate the interaction between NK cells and hepatic stellate cells by acting on either cell type.J Hepatol. 2015 Feb;62(2):398-404. doi: 10.1016/j.jhep.2014.08.038. Epub 2014 Sep 6. J Hepatol. 2015. PMID: 25195554
Cited by
-
The antifibrotic role of natural killer cells in liver fibrosis.Exp Biol Med (Maywood). 2022 Jul;247(14):1235-1243. doi: 10.1177/15353702221092672. Epub 2022 Apr 27. Exp Biol Med (Maywood). 2022. PMID: 35475367 Free PMC article. Review.
-
Involvement of hepatic innate immunity in alcoholic liver disease.Immune Netw. 2010 Dec;10(6):181-7. doi: 10.4110/in.2010.10.6.181. Epub 2010 Dec 31. Immune Netw. 2010. PMID: 21286378 Free PMC article.
-
The CXCR3(+)CD56Bright phenotype characterizes a distinct NK cell subset with anti-fibrotic potential that shows dys-regulated activity in hepatitis C.PLoS One. 2012;7(7):e38846. doi: 10.1371/journal.pone.0038846. Epub 2012 Jul 5. PLoS One. 2012. PMID: 22792160 Free PMC article.
-
Suppression of innate immunity (natural killer cell/interferon-γ) in the advanced stages of liver fibrosis in mice.Hepatology. 2011 Apr;53(4):1342-51. doi: 10.1002/hep.24190. Hepatology. 2011. PMID: 21480338 Free PMC article.
-
Synthetic Retinoids Beyond Cancer Therapy.Annu Rev Pharmacol Toxicol. 2022 Jan 6;62:155-175. doi: 10.1146/annurev-pharmtox-052120-104428. Epub 2021 Sep 13. Annu Rev Pharmacol Toxicol. 2022. PMID: 34516292 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources